Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Clinical trial NCT03946878 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03946878
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Blastoid Variant Mantle Cell Lymphoma CCND1 Protein Overexpression CD20 Positive CD5 Positive FCER2 Negative Pleomorphic Variant Mantle Cell Lymphoma Recurrent Mantle Cell Lymphoma Refractory Mantle Cell Lymphoma t(11;14)(q13;q32)

Start date: 2019-08-13
Primary completion: 2028-02-08
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.